Production of recombinant protein therapeutics in cultivated mammalian cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [8]
In the citing paper
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
From Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing (2010) · cites this paper as Wurm, 2004
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 1×
“In 1973, Graham and van der Eb showed that exposing cells to nanoparticles of DNA and calcium phosphate makes possible DNA transfer into cultivated mammalian cell”
BackgroundEpigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
How introns influence and enhance eukaryotic gene expression
Le Hir, H., Nott, A., & Moore, M. J. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00052-5 · Cited by 734
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462 · cited 1×
“At a concentration of 10–100 μM MSX, resistant clones can be identified in selected NS0 cell populations that have amplified the transgene complex containing the GS gene and the desired gene(s) of interes”
BackgroundGenetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455 · cited 1×
“Nuclear ligases assure the covalent joining of individual plasmid DNA molecule”
BackgroundExpression of recombinant plasmids in mammalian cells Is enhanced by sodium butyrate
Gorman, C. M., Howard, B. H., & Reeves, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.21.7631 · Cited by 367 · cited 1×
“Another way to inhibit silencing is to block deacetylation of histones using butyrat”
BackgroundSilencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Kim, S. J., Kim, N. S., Ryu, C. J., Hong, H. J., & Lee, G. M. (1998) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19980405)58:1<73::aid-bit8>3.0.co;2-r · Cited by 220 · cited 1×
“Thus, it might be advantageous to omit selective drugs once promising clonal cell lines have been identifie”
BackgroundLarge-scale transient expression in mammalian cells for recombinant protein production
Wurm, F., & Bernard, A. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80027-5 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Gorman, C.M., Howard, B.H. & Reeves, R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631–7648 (1983). · DOI · Paper page
Cited by
Items 601–700 of 1,007
Olivier, S., Jacoby, M., Brillon, C., Bouletreau, S., Mollet, T., Nerrière, O., Angel, A., Danet, S., Souttou, B., Guéhenneux, F., et al. (2010) · mAbs · doi:10.4161/mabs.12350 · Cited by 37
“Mammalian cell culture, in particular the Chinese hamster ovary (CHO) cell line, emerged as the expression host of choice for the industrial production of therapeutic glycoproteins because of their capacity for proper protein folding, assembly and post-translational modification.(1) However, a rapid increase in the nu…”
BackgroundExpression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system
Hofmann, I., Wen, Y., Ciferri, C., Schulze, A., Fühner, V., Leong, M. J., Gerber, A., Gerrein, R., Nandi, A., Lilja, A. E., et al. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25670 · Cited by 34
“…used expression systems to produce therapeutic proteins (Birch and Racher, 2006; Datta et al., 2013; Dorai et al., 2012; Jayapal et al., 2007; Laux 2014; Walsh, 2010) and exhibit high productivities in the g/L range for antibodies and other therapeutic proteins (Huang et al., 2010; Wurm 2004).”
BackgroundTranscriptome dynamics of transgene amplification in Chinese hamster ovary cells
Vishwanathan, N., Le, H., Jacob, N. M., Tsao, Y., Ng, S., Loo, B. L. W., Liu, Z., Kantardjieff, A., & Hu, W. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.25117 · Cited by 34
Aufderheide, M., Förster, C., Beshay, M., Branscheid, D., & Emura, M. (2015) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2015.10.001 · Cited by 34
“The types of bioreactors range from those for suspension cultures to those for adherent growing cells on special matrices (Abbott and Kaplan, 2015; Haldankar et al., 2006; Olmer et al., 2012; Serra et al., 2010; Suck et al., 2010; Wurm, 2004).”
BackgroundCoronel, J., Klausing, S., Heinrich, C., Noll, T., Figueredo‐Cardero, A., & Castilho, L. R. (2016) · Biochemical Engineering Journal · doi:10.1016/j.bej.2016.06.031 · Cited by 38
Croughan, M. S., Giroux, D., Fang, D., & Lee, B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-444-63265-4.00005-4 · Cited by 34
Zamolo, L., Busini, V., Moiani, D., Moscatelli, D., & Carlo, C. (2008) · Biotechnology Progress · doi:10.1021/bp070469z · Cited by 34
Hart, D. S., Harinarayan, C., Malmquist, G., Axén, A., Sharma, M., & van Reis, R. (2008) · Journal of Chromatography A · doi:10.1016/j.chroma.2008.11.083 · Cited by 34
RNA interference technology to improve recombinant protein production in Chinese hamster ovary cells
Wu, S. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.03.002 · Cited by 48
He, L., Winterrowd, C. A., Kadura, I. A., & Frye, C. C. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24428 · Cited by 34
Recombinant production of the antibody fragment D1.3 scFv with different Bacillus strains
Lakowitz, A., Krull, R., & Biedendieck, R. (2017) · Microbial Cell Factories · doi:10.1186/s12934-017-0625-9 · Cited by 34
Kozma, B., Salgó, A., & Gergely, S. (2019) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-019-02091-z · Cited by 37
cMyc increases cell number through uncoupling of cell division from cell size in CHO cells
Kuystermans, D., & Al-Rubeai, M. (2009) · BMC Biotechnology · doi:10.1186/1472-6750-9-76 · Cited by 33
“The relatively high cell numbers achieved over more than two decades of process optimization strategies utilising media and fed batch cultivation improvements [1,2] resulted in product titres of more than 5 g/l.”
BackgroundEfficiency improvement of an antibody production process by increasing the inoculum density
Hecht, V., Duvar, S., Ziehr, H., Burg, J., & Jockwer, A. (2014) · Biotechnology Progress · doi:10.1002/btpr.1887 · Cited by 37
“The majority of these antibodies are produced by mammalian cells, mainly CHO, NS0, or SP2/0, because of their ability to perform human-like posttranslational modification.(3) In general, antibodies are high dose products, which have to be applied over prolonged periods.”
BackgroundCell factory engineering: Challenges and opportunities for synthetic biology applications
Bachhav, B., de Rossi, J., Llanos, C. P., & Segatori, L. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28365 · Cited by 36
“In the multipromoter single vector design, each transgene is transcribed independently; as a result, this method lacks control over the relative expression levels of LC and HC (Rita Costa et al., 2010; Wurm, 2004).”
MethodBacon, C. L., Singleton, E., BRADY, B., WHITE, B., Nolan, B., Gilmore, R., RYAN, C., Keohane, C., Jenkins, P. V., & O’Donnell, J. S. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02430.x · Cited by 34
Nematpour, F., Mahboudi, F., Vaziri, B., Khalaj, V., Ahmadi, S., Ahmadi, M., Ebadat, S., & Davami, F. (2017) · BMC Biotechnology · doi:10.1186/s12896-017-0330-0 · Cited by 34
“However, generation of stable and highyielding mammalian cell lines remain one of the most significant challenging issues facing researchers in the field of cell line development [5, 6].”
BackgroundHollow microcarriers for large‐scale expansion of anchorage‐dependent cells in a stirred bioreactor
YekrangSafakar, A., Acun, A., Choi, J., Song, E., Zorlutuna, P., & Park, K. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26601 · Cited by 33
“Especially, mammalian cells are often the preferred expression systems for producing complex biopharmaceutics (Sethuraman and Stadheim, 2006; Wurm, 2004), because they possess more human-compatible post-transcriptional metabolic machinery.”
BackgroundInfluentialJazayeri, S. H., Amiri‐Yekta, A., Bahrami, S., Gourabi, H., Sanati, M. H., & Khorramizadeh, M. R. (2018) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-017-2689-8 · Cited by 38
“strategies have focused on enhancing time integral of viable cell density (IVCD) and specific protein productivity (Qp) [96].”
BackgroundRapid characterization of secreted recombinant proteins by native mass spectrometry
Ben‐Nissan, G., Vimer, S., Warszawski, S., Katz, A. B., Yona, M., Unger, T., Peleg, Y., Morgenstern, D., Cohen‐Dvashi, H., Diskin, R., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0231-3 · Cited by 35
Intensification of large-scale cell culture processes
Jordan, M., Kinnon, N. M., Monchois, V., Stettler, M., & Broly, H. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.11.008 · Cited by 34
Advances in novel vaccines for foot and mouth disease: focus on recombinant empty capsids
Mignaqui, A. C., Ruiz, V., Durocher, Y., & Wigdorovitz, A. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2018.1554619 · Cited by 34
“Although the development of a stable cell line is time-consuming, once established, the recombinant cell line represents a perpetual source of the recombinant protein [49].”
BackgroundNew developments in online OUR monitoring and its application to animal cell cultures
Martínez‐Monge, I., Román, R., Comas, P., Fontova, A., Lecina, M., Casablancas, A., & Cairó, J. J. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09989-4 · Cited by 35
Towards engineering and production of artificial spider silk using tools of synthetic biology
Poddar, H., Breitling, R., & Takano, E. (2020) · Engineering Biology · doi:10.1049/enb.2019.0017 · Cited by 37
Inhibition of cGAS-Mediated Interferon Response Facilitates Transgene Expression
Fu, Y., Fang, Y., Lin, Z., Yang, L., Zheng, L., Hu, H., Yu, T., Huang, B., Chen, S., Wang, H., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101026 · Cited by 33
“…genes of interest into cells (Kim and Eberwine, 2010) and has been widely used in the study of gene function, producing recombinant proteins including monoclonal antibodies for therapeutic purpose (Jager et al., 2013; Wurm, 2004), and treatment of genetic diseases (Cavazzana-Calvo et al., 2000).”
BackgroundEisenhut, P., Marx, N., Borsi, G., Papež, M., Ruggeri, C., Baumann, M., & Borth, N. (2023) · New Biotechnology · doi:10.1016/j.nbt.2023.11.003 · Cited by 37
Michiels, J.-F., Barbau, J., Boel, S. D., Dessy, S., Agathos, S. N., & Schneider, Y. (2010) · Process Biochemistry · doi:10.1016/j.procbio.2010.11.012 · Cited by 37
Expression of soluble and active interferon consensus in SUMO fusion expression system in E. coli
Peciak, K., Tommasi, R., Choi, J.-W., Brocchini, S., & Laurine, E. (2014) · Protein Expression and Purification · doi:10.1016/j.pep.2014.03.009 · Cited by 36
“Although there are many advantages of mammalian expression systems [42] E.”
BackgroundBacterial artificial chromosome library for genome‐wide analysis of Chinese hamster ovary cells
Ōmasa, T., Cao, Y., Park, J. Y., Takagi, Y., Kimura, S., Yano, H., Honda, K., Asakawa, S., Shimizu, N., & Ohtake, H. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22463 · Cited by 33
“The proline-requiring CHO-K1 (Kao and Puck, 1968) and the dihydrofolate reductase (DHFR)-deficient CHO DG44 (Urlaub and Chasin, 1980) cell lines are the most widely used for scientific research and industrial applications (Griffin et al., 2007; Wurm, 2004).”
BackgroundAntibody Expression and Production
Al‐Rubeai, M. (2011) · Cell engineering · doi:10.1007/978-94-007-1257-7 · Cited by 38
Edros, R. Z., McDonnell, S., & Al‐Rubeai, M. (2014) · BMC Biotechnology · doi:10.1186/1472-6750-14-15 · Cited by 40
Vergès-Castillo, A., González-Vargas, I. A., Muñoz‐Cueto, J. A., Martín-Robles, Á. J., & Pendón, C. (2021) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2021.110626 · Cited by 33
Virus-like particle-based nanocarriers as an emerging platform for drug delivery
Yuan, B., Liu, Y., Lv, M., Sui, Y., Hou, S., Yang, T., Belhadj, Z., Zhou, Y., Chang, N., Ren, Y., et al. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2193358 · Cited by 35
“Mammalian cell systems Mammalian cell cultures have been developed as a source of commercial therapeutic proteins for more than 20 years [140].”
BackgroundCurrent state and perspectives on erythropoietin production
Lee, J. S., Ha, T. K., Lee, S. J., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4291-x · Cited by 43
“However, their performances with regard to cell growth and protein production are similar to or superior to those of the serumcontaining media (Wurm 2004).”
BackgroundEngineering the supply chain for protein production/secretion in yeasts and mammalian cells
Klein, T., Niklas, J., & Heinzle, E. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-014-1569-2 · Cited by 36
“In mammalian cells, secretory capacity is usually not the limiting factor and engineering strategies rather focus on the construction of stable cell lines and on process, media and feeding conditions which result in high culture longevity, high integral viable cell density, process robustness and eventually high titer…”
BackgroundMathias, S., Fischer, S., Handrick, R., Fieder, J., Schulz, P., Bradl, H., Gorr, I. H., Gamer, M., & Otte, K. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.02.009 · Cited by 34
Fahey, W., Jeffers, P., & Carroll, P. (2020) · Computers in Industry · doi:10.1016/j.compind.2019.103153 · Cited by 32
Blanco, N., Williams, A. J., Tang, D., Zhan, D., Misaghi, S., Kelley, R. F., & Simmons, L. C. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27347 · Cited by 33
“Chinese hamster ovary (CHO) cells are currently the primary host for the biopharmaceutical industry (Dhara, Naik, Majewska, & Betenbaugh, 2018; Kunert & Reinhart, 2016; Tripathi & Shrivastava, 2019; Walsh, 2018; Wurm, 2004).”
BackgroundAlden, N., Raju, R., McElearney, K., Lambropoulos, J., Kshirsagar, R., Gilbert, A., & Lee, K. (2020) · Metabolites · doi:10.3390/metabo10050199 · Cited by 34
“Advances in process control, medium formulation, and host cell engineering have dramatically increased the volumetric productivity of CHO cell lines [2], with titers for some products reaching 10 grams per liter or higher [3].”
BackgroundSrirangan, K., Loignon, M., & Durocher, Y. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1768043 · Cited by 34
“If the transgene is integrated into the host genome at positions adjacent to centromeric heterochromatins, this can also lead to ectopic expression patterns within the clonal population and occasional gene silencing – a phenomenon known as position effect variegation [9,18].”
BackgroundDesign of transfections: Implementation of design of experiments for cell transfection fine tuning
Mancinelli, S., Turcato, A., Kisslinger, A., Bongiovanni, A., Zazzu, V., Lanati, A., & Liguori, G. L. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27918 · Cited by 33
“…the induced pluripotent stem (iPS) cells to be used as models of disease and/or in patient ‐ specific cell therapy (Nishikawa et al., 2008; Shankar et al., 2020; Takahashi & Yamanaka, 2006) as well as in many bioprocesses for the production of clinical ‐ grade recombinant bio-logics (Wurm, 2004).”
Nair, A. R., Xie, J., & Hermiston, T. W. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-178 · Cited by 33
“Both these markers have the advantage of supporting amplification of the copy number of the integrated DNA by exposure of selected cells to increasing amounts of methotrexate (MTX) or methionine sulphoximine (MSX), respectively [6].”
BackgroundPark, J. H., Wang, Z., Jeong, H., Park, H. H., Kim, B., Tan, W., Choi, S. S., & Park, T. H. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4203-0 · Cited by 32
“However, adhesion culture cannot be used for large-scale production of recombinant proteins (Wurm 2004).”
Vector fragmentation: Characterizing vector integrity in transfected clones by Southern blotting
Ng, S. K., Lin, W., Sachdeva, R., Wang, D. I. C., & Yap, M. G. S. (2009) · Biotechnology Progress · doi:10.1002/btpr.281 · Cited by 32
Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cells
Nallet, S., Fornelli, L., Schmitt, S., Parra, J., Baldi, L., Tsybin, Y. O., & Wurm, F. M. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.02.003 · Cited by 36
Self-citationHumphries‐Bickley, T., Castillo‐Pichardo, L., Corujo, F., Duconge-Soler, J., O'Farril, E. H., Vlaar, C. P., Rodríguez‐Orengo, J. F., Cubano, L. A., & Dharmawardhane, S. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.12.021 · Cited by 33
“In general, most small molecule drug compounds show greater stability compared to biological therapeutics [20-22].”
BackgroundCharacterization of mammalian cell culture raw materials by combining spectroscopy and chemometrics
Trunfio, N., Lee, H., Starkey, J., Agarabi, C., Liu, J., & Yoon, S. (2017) · Biotechnology Progress · doi:10.1002/btpr.2480 · Cited by 32
“assembly and post-translational modification, making them the optimal choice for producing recombinant proteins with clinical applications.(1) Furthermore, specific mammalian cell lines, such as those derived from Chinese hamster ovary (CHO) cell lines are preferred.”
BackgroundKuwae, S., Ichiko, M., & Doi, T. (2018) · Cytotechnology · doi:10.1007/s10616-017-0185-1 · Cited by 36
“1–1 g/L in the 1990s, which was then they improved to 1–10 g/L in the 2000s (Huang et al. 2010; Li et al. 2010; Wurm 2004).”
BackgroundInfluentialOkonkowski, J., Balasubramanian, U., Seamans, C., Fries, S., Zhang, J., Salmon, P. M., Robinson, D., & Chartrain, M. M. (2007) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.103.50 · Cited by 32
Luo, J., Remy, A., & Zhang, Y. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00579 · Cited by 35
Abbott, M. S. R., Brain, C. M., Harvey, A., Morrison, M. I., & Perez, G. V. (2015) · Chemical Engineering Science · doi:10.1016/j.ces.2015.07.045 · Cited by 33
Engineering a mammalian super producer
Dietmair, S., Nielsen, L. K., & Timmins, N. E. (2011) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.2576 · Cited by 39
Hansen, H. G., Nilsson, C. N., Lund, A. M., Kol, S., Grav, L. M., Lundqvist, M., Rockberg, J., Lee, G. M., Andersen, M. R., & Kildegaard, H. F. (2015) · Scientific Reports · doi:10.1038/srep18016 · Cited by 34
“(4) Upon addition of GFP1–10OPT to supernatants, relative product titers of supernatants are determined by split-GFP complementation.”
BackgroundInfluentialCharacterizing steady states of genome-scale metabolic networks in continuous cell cultures
Fernández-de-Cossio-Díaz, J., León, K., & Mulet, R. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005835 · Cited by 35
Chen, Y.-J., Chen, M. J., Hsieh, Y.-C., Su, Y.-C., Wang, C.-H., Cheng, C., Kao, A., Wang, K., Cheng, J., & Chuang, K.-H. (2018) · Scientific Reports · doi:10.1038/s41598-018-36192-8 · Cited by 31
Siemensma, A. D., Babcock, J. F., Wilcox, C., & Huttinga, H. H. (2008) · Springer eBooks · doi:10.1007/978-1-4020-6674-0_3 · Cited by 31
“stable expression systems for heterogonous genes ( Wurm 1997, 2004 ).”
BackgroundKontturi, L.-S., Collin, E. C., Murtomäki, L. S., Pandit, A. S., Yliperttula, M. L., & Urtti, A. O. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.10.005 · Cited by 32
“, selection of promoter and enhancer elements, addition of specific sequences for stabilization and targeting, and codon optimization for enhanced translation) can be used to obtain the desired production level of the recombinant product [66–68].”
BackgroundmRNA stability and antibody production in CHO cells: Improvement through gene optimization
Hung, F., Deng, L., Ravnikar, P. D., Condon, R. G. G., Li, B., Do, L., Saha, D. P., Tsao, Y., Merchant, A., Liu, Z., et al. (2010) · Biotechnology Journal · doi:10.1002/biot.200900192 · Cited by 37
Translatome analysis of CHO cells to identify key growth genes
Courtes, F. C., Lin, J., Lim, H. L., Ng, S. W., Wong, N. S. C., Koh, G., Vardy, L. A., Yap, M. G. S., Loo, B. L. W., & Lee, D. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.07.010 · Cited by 38
Tharmalingam, T., Sunley, K., Spearman, M. A., & Butler, M. (2011) · Molecular Biotechnology · doi:10.1007/s12033-011-9401-y · Cited by 31
“This can be attributed to several technical advances [28, 29].”
BackgroundKumar, N., & Borth, N. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.004 · Cited by 36
Zuberbühler, K., Palumbo, A., Bacci, C., Giovannoni, L., Sommavilla, R., Kaspar, M., Trachsel, E., & Neri, D. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn068 · Cited by 31
“While the expression of full immunoglobulins in bacteria (Simmons et al., 2002; Mazor et al., 2007) and in yeast (Li et al., 2006) has recently been reported, antibodies in IgG format are typically over-expressed in mammalian cells for pharmaceutical applications (Wurm, 2004).”
BackgroundPereira, A. G. M., Templeton, N., & Young, J. D. (2014) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.65 · Cited by 37
Air sparging for prevention of antibody disulfide bond reduction in harvested CHO cell culture fluid
Mun, M., Khoo, S., Minh, A. D., Dvornicky, J., Trexler‐Schmidt, M., Kao, Y., & Laird, M. W. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25495 · Cited by 31
The Upstream Process: Principal Modes of Operation
Lindskog, E. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-100623-8.00031-1 · Cited by 47
Hu, X., Ma, Q., & Zhang, S. (2006) · Biotechnology Journal · doi:10.1002/biot.200600083 · Cited by 31
“The high demand for therapeutic mAbs will dictate the use of mammalian cell cultures as the key technology for the foreseeable future [20, 21].”
BackgroundUsing matrix attachment regions to improve recombinant protein production
Harraghy, N., Buceta, M., Regamey, A., Girod, P.-A., & Mermod, N. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-352-3_7 · Cited by 30
Liste‐Calleja, L., Lecina, M., & Cairó, J. J. (2013) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2013.09.014 · Cited by 38
Pieper, L. A., Strotbek, M., Wenger, T., Gamer, M., Olayioye, M. A., & Haußer, A. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.01.003 · Cited by 32
Wang, B., Albanetti, T., Miró-Quesada, G., Flack, L., Li, L., Klover, J., Burson, K., Evans, K., Ivory, W., Bowen, M. A., et al. (2018) · Biotechnology Progress · doi:10.1002/btpr.2721 · Cited by 30
“Successive screening steps narrow the initial pool of cell lines to a small number for evaluation in bioreactors to choose the final clone for production of clinical and commercial therapeutic protein product.(4) Production cell lines are clonally-derived from single cells to meet regulatory expectations and require d…”
BackgroundA platform for context-specific genetic engineering of recombinant protein production by CHO cells
Cartwright, J. F., Arnall, C. L., Patel, Y. D., Barber, N., Lovelady, C. S., Rosignoli, G., Harris, C. L., Dunn, S., Field, R. P., Dean, G., et al. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.02.012 · Cited by 33
Dielectric spectroscopy‐based estimation of VCD in CHO cell culture
Lee, H. W., Carvell, J. P., Brorson, K., & Yoon, S. (2014) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.4522 · Cited by 30
Bacterial artificial chromosomes improve recombinant protein production in mammalian cells
Blaas, L., Musteanu, M., Eferl, R., Bauer, A., & Casanova, E. (2009) · BMC Biotechnology · doi:10.1186/1472-6750-9-3 · Cited by 30
“Background Recombinant protein production in mammalian cells is an important topic in biotechnology [1].”
Vassanelli, S., Bandiera, L., Borgo, M., Cellere, G., Santoni, L., Bersani, C., Salamon, M., Zaccolo, M., Lorenzelli, L., Girardi, S., et al. (2008) · New Biotechnology · doi:10.1016/j.nbt.2008.03.002 · Cited by 32
Reisinger, H., Steinfellner, W., Stern, B., Katinger, H. W. D., & Kunert, R. (2008) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-008-1701-1 · Cited by 30
“One can assume that this is caused by a positioning effect of the target gene in the chromosome (Jiang et al. 2006; Wurm 2004).”
BackgroundInfluentialChanges in intracellular ATP ‐content of CHO cells as response to hyperosmolality
Pfizenmaier, J., Matuszczyk, J., & Takors, R. (2015) · Biotechnology Progress · doi:10.1002/btpr.2143 · Cited by 35
“human embryonic kidney (HEK), baby hamster kidney (BHK), or mouse myeloma (NS0) cells.(1,2) Despite the variety of differ-”
BackgroundJolicoeur, P., & Tacey, R. L. (2012) · Bioanalysis · doi:10.4155/bio.12.285 · Cited by 30
Otte, A. P., Kwaks, T., vanBlokland, R. J. M., Sewalt, R. G. A. B., Verhees, J., Klaren, V. N. A., Siersma, T. K., Korse, H. J. W. M., Teunissen, N. C., Botschuijver, S., et al. (2007) · Biotechnology Progress · doi:10.1002/bp070107r · Cited by 33
Disposable 600-mL orbitally shaken bioreactor for mammalian cell cultivation in suspension
Monteil, D., Tontodonati, G., Ghimire, S., Baldi, L., Hacker, D., Bürki, C., & Wurm, F. (2013) · Biochemical Engineering Journal · doi:10.1016/j.bej.2013.04.008 · Cited by 26
Self-citationATF for cell culture harvest clarification: mechanistic modelling and comparison with TFF
Hadpe, S. R., Sharma, A. K., Mohite, V. V., & Rathore, A. S. (2016) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.5165 · Cited by 30
Application of CRISPR/Cas9 Genome Editing to Improve Recombinant Protein Production in CHO Cells.
Grav, L. M., Karottki, K. J. L. C., Lee, J. S., & Kildegaard, H. F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6972-2_7 · Cited by 29
Betts, Z., & Dickson, A. J. (2015) · Molecular Biotechnology · doi:10.1007/s12033-015-9877-y · Cited by 31
“In order to isolate a stable high-producing clone, a large number of clones need to be screened [8–10].”
BackgroundProduction of Chimeric Heavy-Chain Antibodies
Zhang, J., MacKenzie, R., & Durocher, Y. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-554-1_17 · Cited by 30
Backliwal, G., Hildinger, M., Chenuet, S., DeJesus, M., & Wurm, F. M. (2008) · New Biotechnology · doi:10.1016/j.nbt.2008.08.007 · Cited by 30
Self-citationLi, Y., Tian, Z., Xu, D., Wang, X.-Y., & Wang, T. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4351-0 · Cited by 31
Steinhoff, R., Karst, D. J., Steinebach, F., Kopp, M. R. G., Schmidt, G. W., Stettler, A., Krismer, J., Šoóš, M., Pabst, M., Hierlemann, A. R., et al. (2015) · Methods · doi:10.1016/j.ymeth.2015.12.011 · Cited by 29
Transcriptomic analysis of clonal growth rate variation during CHO cell line development
Doolan, P., Clarke, C., Kinsella, P., Breen, L., Meleady, P., Leonard, M. W., Zhang, L., CLYNES, M. M., Aherne, S. T., & Barron, N. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.04.014 · Cited by 29
Zúñiga, R. A., Gutiérrez-González, M., Collazo, N., Sotelo, P. H., Ribeiro, C. H., Altamirano, C., Lorenzo, C., Aguillón, J. C., & Molina, M. C. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-019-0187-y · Cited by 29
Expansion processes for cell-based therapies
Scibona, E., & Morbidelli, M. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107455 · Cited by 30
Wu, Z., Wang, H., Wu, J., Huang, Y., Zhao, X., Nguyen, J. B., Rosconi, M. P., Pyles, E. A., Qiu, H., & Li, N. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115147 · Cited by 29
Fluorescence‐based soft sensor for at situ monitoring of chinese hamster ovary cell cultures
Ohadi, K., Aghamohseni, H., Legge, R. L., & Budman, H. M. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25222 · Cited by 29
Paluzzi, J.-P. V., Young, P., Defferrari, M. S., Orchard, I., Carlini, C. R., & O’Donnell, M. J. (2011) · Peptides · doi:10.1016/j.peptides.2011.10.025 · Cited by 29
Masterton, R. J., & Smales, C. M. (2014) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.14.3 · Cited by 29
Zimmer, A., Mueller, R., Wehsling, M., Schnellbaecher, A., & von Hagen, J. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.06.026 · Cited by 30
Transient gene expression in HEK293 and vero cells immobilised on microcarriers
Fliedl, L., & Kaisermayer, C. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.02.007 · Cited by 29
Adame-Gallegos, J. R., Shi, J., McIntosh, R. S., & Pleass, R. J. (2012) · Experimental Parasitology · doi:10.1016/j.exppara.2012.02.003 · Cited by 29
“CHO and HEK-293 mammalian cell lines are widely used in the production of recombinant proteins (Wurm, 2004).”
BackgroundInfluentialKadlecová, Z., Rajendra, Y., Matasci, M., Hacker, D. L., Baldi, L., Wurm, F. M., & Klok, H. (2012) · Macromolecular Bioscience · doi:10.1002/mabi.201100519 · Cited by 29
Self-citationKelly, P. S., Clarke, C., Costello, A., Monger, C., Meiller, J., Dhiman, H., Borth, N., Betenbaugh, M. J., CLYNES, M. M., & Barron, N. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.02.001 · Cited by 31
Brinkmann, A., Elouafiq, S., Pieracci, J. P., & Westoby, M. (2018) · Biotechnology Progress · doi:10.1002/btpr.2601 · Cited by 29
“Significant advancements have been made in the culture of mammalian cells over the past few decades, allowing companies to routinely achieve final bioreactor titers of 5–10 g/L or higher.(1,2) However, many of the existing large scale manufacturing facilities were designed for cell culture processes with a maximum tit…”
BackgroundHefzi, H., Martínez‐Monge, I., de Mas, I. M., Cowie, N. L., Toledo, A. G., Noh, S. M., Karottki, K. J. L. C., Decker, M., Arnsdorf, J., Camacho-Zaragoza, J. M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-024-01193-7 · Cited by 32
“Ideally, engineered host cell lines would be compatible with existing CLD workflows, but previous work showed that shRNA-mediated downregulation of Ldha resulted in cells unable to survive the established selection and amplification processes 33,34 .”
Metadata
- Authors
- Wurm, F. M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Wurm, Florian M
- ORCID
- Wurm, Florian M
- Venue
- Nature Biotechnology
- Published
- 2004-11
- Volume
- 22
- Issue
- 11
- Pages
- 1393-1398
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2118540273
- Cited by
- 2,032
- References
- 52
- Citations by year
- 2026: 52 · 2025: 51 · 2024: 66 · 2023: 66 · 2022: 64 · 2021: 77 · 2020: 89 · 2019: 114 · 2018: 162 · 2017: 118 · 2016: 95 · 2015: 135 · 2014: 108 · 2013: 145 · 2012: 111
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant therapeutic proteins, mammalian cell culture, bioreactors, protein folding, post-translational modification, volumetric productivity, culture medium optimization, process control, vector engineering, host cell engineering
- MeSH terms
- Animals, Cells, Cultured, Humans, Mammals, Recombinant Proteins, Transfection, Protein Engineering, Cell Culture Techniques, Bioreactors, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.